The laboratory structure will support venture companies within the Kobe International Business Center (KIBIC) in the Kobe Medical Industry City. The first venture companies will be Epigeneron, an Osaka University venture, aiming for epigenetic drug discovery, and Myolidge, a Kyoto University venture aiming to develop drug discovery tools using iPS cell derived cardiomyocytes.